LAPTM4B-35, a Cancer-Related Gene, Is Associated with Poor Prognosis in TNM Stages I-III Gastric Cancer Patients

Background Lysosome-associated transmembrane protein 4β-35 (LAPTM4B-35), a member of the mammalian 4-tetratransmembrane spanning protein superfamily, has been reported to be overexpressed in several cancers. However the expression of LAPTM4B-35 and its role in the progression of gastric cancer (GC) remains unknown. The aim of this study was to investigate LAPTM4B-35 expression in GC, its potential relevance to clinicopathologic parameters and role of LAPTM4B-35 during gastric carcinogenesis. Methods In the present study, paraffin-embedded specimens with GC (n = 240, including 180 paired specimens) and 24 paired fresh frozen tissues were analyzed. qRT-PCR and immunohistochemistry (IHC) were used to analyze the expression of LAPTM4B-35 in GC. The effects of LAPTM4B-35 on GC cell proliferation, migration and invasion were determined by overexpression and knockdown assays. Results IHC showed that LAPTM4B-35 was expressed in 68.3% (123/180) of GC tissues, while in 16.1% (29/180) of their paired adjacent noncancerous gastric tissues (P = 0.000). LAPTM4B-35 mRNA levels in GC tissues were also significantly elevated when compared with their paired adjacent noncancerous tissues (P = 0.017). Overexpression of LAPTM4B-35 was significantly associated with degree of differentiation, depth of invasion, lymphovascular invasion and lymph node metastasis (P<0.05). Kaplan-Meier survival curves revealed that patients with LAPTM4B-35 expression had a significant decrease in overall survival (OS) in stages I-III GC patients (P = 0.006). Multivariate analysis showed high expression of LAPTM4B-35 was an independent prognostic factor for OS in stage I-III GC patients (P = 0.025). Conclusion These findings indicate that LAPTM4B-35 overexpression may be related to GC progression and poor prognosis, and thus may serve as a new prediction marker of prognosis in GC patients.

[1]  Wei Zhang,et al.  The incidences and mortalities of major cancers in China, 2010 , 2014, Chinese journal of cancer.

[2]  Xiaojun Zhu,et al.  Genome editing with RNA-guided Cas9 nuclease in Zebrafish embryos , 2013, Cell Research.

[3]  Wanqing Chen,et al.  The incidence and mortality of major cancers in China, 2012 , 2013, Chinese journal of cancer.

[4]  Hongbin Wang,et al.  Overexpression of LAPTM4B: an independent prognostic marker in breast cancer , 2013, Journal of Cancer Research and Clinical Oncology.

[5]  Wei Jiang,et al.  Overexpression of LAPTM4B-35 is associated with poor prognosis in colorectal carcinoma. , 2012, American journal of surgery.

[6]  A. Richardson,et al.  The amplified cancer gene LAPTM4B promotes tumor growth and tolerance to stress through the induction of autophagy , 2012, Autophagy.

[7]  Xiaoming Ning,et al.  LAPTM4B Overexpression is a Novel Independent Prognostic Marker for Metastatic Ovarian Tumors , 2012, International Journal of Gynecologic Cancer.

[8]  A. Richardson,et al.  Lysosomal transmembrane protein LAPTM4B promotes autophagy and tolerance to metabolic stress in cancer cells. , 2011, Cancer research.

[9]  D. Rotin,et al.  A Role for the Ubiquitin Ligase Nedd4 in Membrane Sorting of LAPTM4 Proteins , 2011, PloS one.

[10]  F. Roviello,et al.  Changing clinical and pathological features of gastric cancer over time , 2011, The British journal of surgery.

[11]  Xia Li,et al.  Over‐expression of LAPTM4B is associated with poor prognosis and chemotherapy resistance in stages III and IV epithelial ovarian cancer , 2011, Journal of surgical oncology.

[12]  J. Rui,et al.  Overexpression of LAPTM4B-35 attenuates epirubucin-induced apoptosis of gallbladder carcinoma GBC-SD cells. , 2011, Surgery.

[13]  M. McNutt,et al.  Combined lysosomal protein transmembrane 4 beta-35 and argininosuccinate synthetase expression predicts clinical outcome in hepatocellular carcinoma patients , 2011, Surgery Today.

[14]  Paolo Bechi,et al.  Genomic and genetic alterations influence the progression of gastric cancer. , 2011, World journal of gastroenterology.

[15]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[16]  H. Li,et al.  LAPTM4B: A novel cancer-associated gene motivates multidrug resistance through efflux and activating PI3K/AKT signaling , 2010, Oncogene.

[17]  M. McNutt,et al.  Overexpression of LAPTM4B-35 promotes growth and metastasis of hepatocellular carcinoma in vitro and in vivo. , 2010, Cancer letters.

[18]  J. Ajani,et al.  Gastric cancer--an enigmatic and heterogeneous disease. , 2010, JAMA.

[19]  J. Rui,et al.  LAPTM4B‐35 is a novel prognostic factor of hepatocellular carcinoma , 2010, Journal of surgical oncology.

[20]  J. Coebergh,et al.  Trends in incidence, treatment and survival of gastric adenocarcinoma between 1990 and 2007: a population-based study in the Netherlands. , 2010, European journal of cancer.

[21]  J. Rui,et al.  Overexpression of LAPTM4B promotes growth of gallbladder carcinoma cells in vitro. , 2010, American journal of surgery.

[22]  Ming-zhu Yin,et al.  LAPTM4B-35 Overexpression Is an Independent Prognostic Marker in Endometrial Carcinoma , 2010, International Journal of Gynecologic Cancer.

[23]  Zoltan Szallasi,et al.  Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer , 2010, Nature Medicine.

[24]  R. Zhou,et al.  LAPTM4B‐35, a novel tetratransmembrane protein and its PPRP motif play critical roles in proliferation and metastatic potential of hepatocellular carcinoma cells , 2009, Cancer science.

[25]  C. O'Morain,et al.  Nature meets nurture: molecular genetics of gastric cancer , 2009, Human Genetics.

[26]  M. Coleman,et al.  Long-term survival expectations of cancer patients in Europe in 2000-2002. , 2009, European journal of cancer.

[27]  J. Rui,et al.  Expression of LAPTM4B-35: a novel marker of progression, invasiveness and poor prognosis of extrahepatic cholangiocarcinoma. , 2008, Cancer letters.

[28]  J. Rui,et al.  Overexpression of LAPTM4B-35 closely correlated with clinicopathological features and post-resectional survival of gallbladder carcinoma. , 2007, European journal of cancer.

[29]  Y. Liu,et al.  Relationship between LAPTM4B gene polymorphism and susceptibility of gastric cancer. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  J. Rui,et al.  Expression of lysosome-associated protein transmembrane 4B-35 in cancer and its correlation with the differentiation status of hepatocellular carcinoma. , 2005, World journal of gastroenterology.

[31]  F. Bosman,et al.  DNA-Ploidy in Advanced Gastric Carcinoma is Less Heterogeneous than in Early Gastric Cancer , 2004, Cellular oncology : the official journal of the International Society for Cellular Oncology.

[32]  J. Rui,et al.  Structure analysis and expressions of a novel tetratransmembrane protein, lysosoma-associated protein transmembrane 4 beta associated with hepatocellular carcinoma. , 2004, World journal of gastroenterology.

[33]  Jun Liu,et al.  Molecular cloning and characterization of LAPTM4B, a novel gene upregulated in hepatocellular carcinoma , 2003, Oncogene.

[34]  Jing He,et al.  [Effects of the novel gene, LAPTM4B, highly expression in hepatocellular carcinoma on cell proliferation and tumorigenesis of NIH3T3 cells]. , 2003, Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences.

[35]  J. Rui,et al.  [Identification and characterization of LAPTM4B encoded by a human hepatocellular carcinoma-associated novel gene]. , 2003, Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences.

[36]  Aller,et al.  Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. , 2002, The New England journal of medicine.

[37]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[38]  Michael R Hamblin,et al.  CA : A Cancer Journal for Clinicians , 2011 .